A cost-utility analysis of long-acting insulin analogues (detemir, glargine and degludec) for the treatment of adult type 1 diabetes in South Africa.

Cost Eff Resour Alloc · 2025 · PMC11931765 · PMID 40122825

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

may be significantno p-value reported

There may be significant differences between the two regimens with regards to clinical outcomes, which should be a topic for further research.

also in 13,097 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.